The following is a summary of the Collegium Pharmaceutical, Inc. (COLL) Q3 2024 Earnings Call Transcript:
Financial Performance:
Collegium reported record total net product revenues of $159.3 million in Q3 2024, up 17% year-over-year.
Adjusted EBITDA was a record $105.1 million, up 18% year-over-year.
Financial growth was particularly strong in the Pain portfolio, and Jornay PM is expected to generate over $100 million in net revenue in 2024.
Business Progress:
Completed the acquisition of Ironshore, integrating Jornay PM into the ADHD market.
Jornay PM prescriptions increased 31.2% year-over-year, highlighted by back-to-school season growth.
Introduced new CEO Vikram Karnani, a seasoned biopharmaceutical executive, to lead future growth and expansion.
Opportunities:
Integration of Ironshore's Jornay PM broadens Collegium's commercial presence into the large ADHD market, enhancing revenue diversification beyond pain management.
Risks:
No explicit risks detected.
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
